Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma.
Tarhini AA, Eroglu Z, Eljilany I, Zager JS, Gonzalez RJ, Sarnaik AA, Cruse CW, Khushalani NI, De Aquino DB, Abraham E, Acevedo DM, Richards A, Schell MJ, Kalos D, Chen PL, Messina JL, Canton DA, Sondak VK. Tarhini AA, et al. Among authors: khushalani ni. Clin Cancer Res. 2024 Dec 2;30(23):5333-5341. doi: 10.1158/1078-0432.CCR-24-2768. Clin Cancer Res. 2024. PMID: 39417680
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. Hughes BGM, et al. Among authors: khushalani ni. J Am Acad Dermatol. 2025 Jan;92(1):68-77. doi: 10.1016/j.jaad.2024.06.108. Epub 2024 Sep 7. J Am Acad Dermatol. 2025. PMID: 39245360 Clinical Trial.
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma.
Ramadoss T, Nichols M, Palacios C, Eroglu Z, Markowitz J, Karapetyan L, Tarhini AA, Wuthrick EJ, Sondak VK, Khushalani NI, Tsai KY, Brohl AS. Ramadoss T, et al. Among authors: khushalani ni. J Immunother Cancer. 2024 Sep 5;12(9):e009816. doi: 10.1136/jitc-2024-009816. J Immunother Cancer. 2024. PMID: 39242118 Free PMC article.
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
Weber J, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelson M, Ascierto PA, Larkin J. Weber J, et al. Among authors: khushalani ni. J Clin Oncol. 2024 Nov;42(31):3702-3712. doi: 10.1200/JCO.23.01448. Epub 2024 Aug 5. J Clin Oncol. 2024. PMID: 39102624 Free PMC article. Clinical Trial.
Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy.
Reinstein ZZ, Zhang Y, Ospina OE, Nichols MD, Chu VA, Pulido AM, Prieto K, Nguyen JV, Yin R, Moran Segura C, Usman A, Sell B, Ng S, de la Iglesia JV, Chandra S, Sosman JA, Cho RJ, Cheng JB, Ivanova E, Koralov SB, Slebos RJC, Chung CH, Khushalani NI, Messina JL, Sarnaik AA, Zager JS, Sondak VK, Vaske C, Kim S, Brohl AS, Mi X, Pierce BG, Wang X, Fridley BL, Tsai KY, Choi J. Reinstein ZZ, et al. Among authors: khushalani ni. Cancer Discov. 2024 Sep 4;14(9):1631-1652. doi: 10.1158/2159-8290.CD-23-0798. Cancer Discov. 2024. PMID: 39058036
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
Gogas H, Ravimohan S, Datta A, Chhibber A, Couselo EM, Diab A, Pereira C, Quéreux G, Sandhu S, Curti B, Khushalani NI, Taylor MH, Daniels GA, Spreafico A, Meniawy T, Van Den Eertwegh AJM, Sun Y, Arriaga Y, Zhou M, Long GV, Lebbé C. Gogas H, et al. Among authors: khushalani ni. NPJ Precis Oncol. 2024 Jul 19;8(1):150. doi: 10.1038/s41698-024-00641-7. NPJ Precis Oncol. 2024. PMID: 39025948 Free PMC article.
Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy.
Hoogland AI, Brohl AS, Small BJ, Michael L, Wuthrick E, Eroglu Z, Blakaj D, Verschraegen C, Khushalani NI, Jim HSL, Kim S. Hoogland AI, et al. Among authors: khushalani ni. Cancer Med. 2024 Jul;13(14):e7464. doi: 10.1002/cam4.7464. Cancer Med. 2024. PMID: 39021272 Free PMC article. Clinical Trial.
Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome.
Lukowiak TM, Cahn B, Samie F, Leffell DJ, Oro A, Kibbi N, Kheterpal M, Babakoohi S, Khushalani NI, Stephenson A, Ma MS, Shi VJ, Ahmed A, Koza E, Haq M, Yi MD, Nadir U, Yoo S, Brieva JC, Lucas J, Haber R, Alam M. Lukowiak TM, et al. Among authors: khushalani ni. Arch Dermatol Res. 2024 Jul 5;316(7):453. doi: 10.1007/s00403-024-03157-z. Arch Dermatol Res. 2024. PMID: 38967654 No abstract available.
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.
Tometich DB, Geiss C, Maconi ML, Chavez M, Hoogland AI, Li X, Nieves-Lopez A, Rodriguez Y, Bryant C, Brohl AS, Eroglu Z, Markowitz J, Tarhini AA, Hwu P, Khushalani NI, Jim HSL. Tometich DB, et al. Among authors: khushalani ni. Support Care Cancer. 2024 May 6;32(6):330. doi: 10.1007/s00520-024-08538-8. Support Care Cancer. 2024. PMID: 38709312
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0.
Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Dehlawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. Markowitz J, et al. Among authors: khushalani ni. Mol Cancer Ther. 2024 Aug 1;23(8):1139-1143. doi: 10.1158/1535-7163.MCT-23-0652. Mol Cancer Ther. 2024. PMID: 38657233 Free PMC article. Clinical Trial.
113 results